The mechanism of action of oral antidiabetic drugs: A review of recent literature

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 13, Issue 3, 2008, Pages 80-89

  Bosenberg L H ^a   Van Zyl, D G ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE; VILDAGLIPTIN; WARFARIN;

ABDOMINAL DISCOMFORT; ACUTE INTERMITTENT PORPHYRIA; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; EDEMA; FLATULENCE; FLUID RETENTION; FRACTURE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREAS ISLET CELL FUNCTION; PREGNANCY; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TERATOGENICITY; TREATMENT CONTRAINDICATION; WEIGHT GAIN;

EID: 59849110432     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: 10.1080/22201009.2008.10872177     Document Type: Review

References (57)

1. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 52: 837-853.
2. American Diabetes Association, European Association for the Study of Diabetes; International Federation of Clinical Chemistry and Laboratory; International Diabetes Federation Medicine. Consensus statement on the worldwide standardization of the HbA1c measurement. Diabetologia 2007; 50(10): 2042-2043.
3. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the management of diabetes mellitus. Endo Pract 2007; 13(suppl 1): 1-68.
4. Krentz A, Bailey C. Oral antidiabetic drugs - current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385-411.
5. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning the β cell high-affinity sulphonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423-426.
6. Pratley R, Woyer C. The role of impaired insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001; 44: 929-945
7. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycaemic activity of Glyburide (Glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026-1030.
8. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157. 1681-1686.
9. Bressler R, Johnson DG Pharmacological regulation of blood glucose levels in non-insulin dependant diabetes mellitus. Arch Intern Med 1997; 157: 836-848.
10. Jönsson A, Rydberg Y, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145.
11. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998; 53(6): 429-435
12. Tessier D, Dawson K, Tétrault JP, Bravo G, Meneilly GS. Glibenclamide vs. gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11(10): 974-980.
13. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type diabetes mellitus Drugs 1998; 55(4): 563-584.
14. Nathan DM. Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: Update regarding the thiazolidinediones. Diabetologia 2008; 51(1): 8-11.
15. DoFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 2000; 133(1). 73-74
16. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33(1): 119-124.
17. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174(2): 169-174.
18. Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174(2): 185-186.
19. Wilson SH. Kennedy FP, Garrat KN. Optimisation of the management of patients with coronary artery disease and type 2 diabetes mellitus. Drugs Aging 2001; 18: 325-333.
20. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002: 287(3): 360-372.
21. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 79(2): 196-203.
22. Chounta A, Zouridakis S, Ellinas C, et al. Cholestatic liver injury after glimepiride therapy. J Hepatol 2005; 42(6): 944-946.
23. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47(3): 345-351.
24. Culy CR. Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61(11): 1625-1660.
25. Dunn C, Faulds D Nateglinide. Drugs 2000; 60: 607-615.
26. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166) Diabetes Care 2001; 24(7): 1221-1225.
27. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001; 24(1): 11-15.
28. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22(1). 119-124.
29. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002, 51(8): 2420-2425.
30. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310(5754): 1642-1646.
31. Klip A, Leiter LA. Cellular mechanism of action of Metformin. Diabetes Care 1990; 13(6): 696-704.
32. Bailey CJ. Metformin. N Engl J Med 1996; 334(9): 574-579.
33. Nestler JE. Metformin for the treatment of polycystic ovarian syndrome. N Engl J Med 2008; 358(1): 47-54.
34. Roiwan JA, Hague WM, Gao W, Battin MR, Moore P. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
35. Varughese GI, Tahrani AA, Scarpello JH. The long and short of metformin-related vitamin B12 deficiency. Arch Intern Med 2007; 167(7): 729-730
36. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147(8): 578-581.
37. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAtone Clinical Trial In macroVascular Events): a randomized control trial. Lancet 2005; 366: 1279-1289.
38. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2008; 4 Aug.
39. Nesto RW, Bell D, Bonow, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.
40. Erdmann E, Wilcox RG Weighing up the cardiovascular benefits of thiazolidinedione therapy the impact of increased risk of heart failure. Eur Heart J 2008, 29(1): 12-20.
41. Patel C, Wyne KC, McGuire DK. Thiazolidinediones, peripheral oedema and congestive cardiac failure: What is the evidence? Diab Vasc Dis Res 2005, 2(2): 61-66.
42. Kahn SE, Zinman B, Lachin JM. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from ADOPT. Diabetes Care 2008, 31(5): 845-851.
43. Takeda Pharmaceutical Co. Observation of an increased incidence of fractures in female patients who receive long-term treatment with ACTOS (pioglitazone HCL) tablets for type 2 diabetes mellitus (Letter to Health Care Providers). http:/www.fda.gov/medwatch/safety/2007/ Actosmar0807.pdf. (accessed 19 March 2007).
44. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPAR-gamma agonist BRL40653 (rosiglitazone). Calcified Tissue International 2004; 75(4): 329-337.
45. Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized control trial. J Bone Miner Res 2000:15(6): 1006-1013.
46. Semple RK, Krishna K. PPAR-α and human metabolic disease. J Clin Invest 2006; 116: 581-586.
47. Chiasson JL. Prevention of Type 2 diabetes: fact or fiction? Expert Opin Pharmacother 2007; 8(18): 3147-3158
48. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006; 12 (suppl 1): 25-30.
49. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II Incretin-based therapy and beyond. Circulation 2008; 117(4): 574-584.
50. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 nhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-1705.
51. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007; 24: 223-232.
52. Visbøll T, Brock B, Perrild H, et al. Liraglutide, a once daily human GLP-1 analogue, improves parcreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25(2): 152-156.
53. Idris I, Donnely R. DDP-IV inhibitor: a major new class of oral anti-diabetic drug. Diabetes Obes Metab 2007; 9: 153-156.
54. Rosenstock J, Fitchet M. Vidagliptin: clinical trials a programme in monotherapy and combination therapy for type 2 diabetes. Int J Clin Pract 2008; suppl 159 15-23.
55. Ahrén B, Foley JE. The islet enhancer vildagliptin mechanisms of improved glucose metabolism. Int J Clin Pract 2008, suppl 159: 8-14.
56. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus. Drugs 2004; 63(13): 1419-1432.
57. VanDeKoppel S, Choe NM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008; 14(4): 363-380.